Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (121-130 of 174) with videos related to

Pageof 18
Sort By:
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trialsMattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2022
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic ProfileDavine Hofste Op Bruinink, Rowan Kuiper, Mark van Duin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Pageof 18

Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trialsMattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2022
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic ProfileDavine Hofste Op Bruinink, Rowan Kuiper, Mark van Duin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
Blood Cancer Journal|June 4, 2021
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trialStefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Pageof 18